ABVC BIOPHARMA, INC. (ABVC): auditor change — ABVC BioPharma concludes Q3 2025 financials unreliable; total assets surge 179% to $21.06M

ABVC BIOPHARMA, INC.

Board determined Q3 2025 financials unreliable due to revenue recognition errors ($795,950 reversed) and land valuation error ($798,486 increase).
Company will restate Q3 2025 10-Q; identifies material weakness in internal controls over financial reporting.
FY2025 total assets $21.06M (179% YoY); property/equipment $12.84M (up from $0.51M).
Strategic land acquisitions in Taiwan valued at ~$4.6M (Longtan) and ~$8.0M (Puli) strengthen asset base.
Revenue and EPS not disclosed; licensing model retains economics while reducing cash burn.

item 2.02 item 4.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ABVC BIOPHARMA, INC. reported that prior financial statements should not be relied upon.

Action: non reliance
Auditor: Simon & Edward, LLP

Exact text from the filing

atters disclosed in this Item 4.02 with its independent registered public accounting firm, Simon & Edward, LLP. Due to the above, the Company determined that it has a material weakness in its internal controls over financial reporting and shall include such determination in its Annual Report on Form

View on SEC.gov

Browse all auditor changes →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-023054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.